Listen to all the voices: An advocate's perspective on early access to investigational therapies

Clinical Trials

Volumn 3, Issue 2, 2006, Pages 149-153

  Mayer, Musa ^a  

^a Institute of Medicine Forum on Drug Discovery Development and Translation

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPATHY; BONE MARROW; BREAST CANCER; CHEMOTHERAPY; DRUG MARKETING; EXPERIMENTAL THERAPY; GOVERNMENT; HISTORY OF MEDICINE; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; UNITED STATES;

HEALTH SERVICES ACCESSIBILITY; HUMANS; PATIENT ADVOCACY; THERAPIES, INVESTIGATIONAL; TIME FACTORS; UNITED STATES;

EID: 33645802103     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774506cn144oa     Document Type: Review

References (29)

1. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15.
2. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
3. Williams SF, Mick R, Desser R, Golick J, Beschomer J, Bitran JD. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-30.
4. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-26.
5. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
6. Williams SF Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-47.
7. Peters WP et al. Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin, and carmustine and autologous bone marrow support for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): a preliminary report, Proc of ASCO 1990; 9: 22 (abstract).
8. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-89.
9. Belanger D, Moore M, Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol 1991; 9: 7-16.
10. Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff (Millwood) 2001; 20: 101-17.
11. Peters WP, Rogers MC. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 1994; 330: 7 473-77.
12. Health insurance: coverage of autologous bone marrow transplantation for breast cancer (GAO/HEHS-96-83). http://www.gao.gov/archive/1996/he96083.pdf.
13. Stadtmauer EA, O'Neil A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-76. (for others, see Farquahar, below).
14. Rahman ZU, Frye DK, Buzdar AU et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-77.
15. Weiss RB, Rifkin RM, Stewart FM et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. Lancet 2000; 355: 999-1003.
16. Bezwoda retraction. J Clin Oncol 2001; 19: 2973.
17. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 2005; CD003142.
18. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev 2005; CD003139.
19. Abigail Alliance for Better Access to Developmental Drugs. http://abigail-alliance.org/.
20. Transcript of the November 8, 2005 Meeting of the FDA Oncologic Drugs Advisory Committee, pp. 237-61. http://www.fda.gov/ohrms/dockets/ac/05/ transcripts/20 05-4191T1.pdf.
21. Goldberg P. An 'insurgency' targets randomized trials, demands access to investigational drugs. The Cancer Letter 2005; 31: 2.
22. FDA to patients: Drop dead. Wall Street Journal, September 24, 2002 A18. http://www.mercatus.org/regradar/topnews/archives/003730.php.
23. How about a Kianna's Law? Wall Street Journal, March 24, 2005. http://jiminhofe.com/cgi-data/news_doc/files/210.shtml; http://abigail-alliance. org/3_WSJ_Editorials_ Kiannas_Law.pdf.
24. Goldberg P. Op Cit 1-16.
25. Subpart H-Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Code of Federal Regulations [Title 21, Volume 5, Parts 300 to 499] Department of Health and Human Services http://www.fda.gov/ cder/guidance/append4.pdf.
26. Transcript of ODAC Meeting November 8, 2005, http://www.fda.gov/ohrms/ dockets/ac/05/transcripts/2005-4191T1.pdf.
27. Transcript of ODAC Meeting March 12, 2003, http://www.fda.gov/ohrms/ dockets/ac/03/transcripts/3936T1.htm.
28. Talarico L, Pazdur R. Expanded access program (EAP) to investigational drugs. Proc of ASCO 2004. Abstract 6001 (Abstract, lecture, slides), http://www.asco.org/portal/site/ASCO.
29. Fast Track, Priority Review and Accelerated Approval. From FDA/CDER Oncology Tools website, http://www. accessdata.fda.gov/scripts/cder/onctools/ Accel.cfm.